We are live on ! Find out more
APTO

Aptose Biosciences, Inc.
APTO

Delisted

APTO was delisted on the 1st of April, 2025.

Back to rankings

56 hedge funds and large institutions have $174M invested in Aptose Biosciences, Inc. in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

489% more capital invested

Capital invested by funds: $29.6M → $174M (+$145M)

278% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 9

81% more funds holding

Funds holding: 31 → 56 (+25)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

54% more call options, than puts

Call options by funds: $1.41M | Put options by funds: $918K

Holders
56
Holders Change
+25
Holders Change %
+80.65%
% of All Funds
1.1%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
34
Increased
11
Reduced
7
Closed
9
Calls
$1.41M
Puts
$918K
Net Calls
+$496K
Net Calls Change
+$745K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$13.8M
2
OM
Opaleye Management
Massachusetts
+$9.74M
3
NCM
Nantahala Capital Management
Connecticut
+$5.17M
4
O
OrbiMed
New York
+$3.33M
5
DCM
Driehaus Capital Management
Illinois
+$2.81M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.14M
2
Man Group
Man Group
United Kingdom
-$4.02M
3
Creative Planning
Creative Planning
Kansas
-$156K
4
SMH
Sanders Morris Harris
Texas
-$136K
5
JP Morgan Chase
JP Morgan Chase
New York
-$133K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$34.3M +$5.17M +3,970 +42%
CCM
2
Consonance Capital Management
New York
$27.1M +$13.8M +10,605 New
OM
3
Opaleye Management
Massachusetts
$23.2M +$9.74M +7,478 +467%
DS
4
DRW Securities
Illinois
$21M +$1.59M +1,222 +17%
O
5
OrbiMed
New York
$6.52M +$3.33M +2,556 New
IC
6
Ikarian Capital
Texas
$5.72M +$2.92M +2,244 New
DCM
7
Driehaus Capital Management
Illinois
$5.51M +$2.81M +2,159 New
Millennium Management
8
Millennium Management
New York
$4.71M +$2.4M +1,845 New
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$4.37M -$4.14M -3,175 -65%
PAWC
10
P.A.W. Capital
Connecticut
$3.86M +$521K +400 +36%
PC
11
Polar Capital
United Kingdom
$3.69M +$1.88M +1,444 New
SSA
12
Schonfeld Strategic Advisors
New York
$3.65M +$1.86M +1,429 New
MS
13
Maven Securities
Jersey
$3.45M +$1.74M +1,334 New
LGM
14
Logos Global Management
California
$2.97M +$1.52M +1,164 New
CA
15
Corriente Advisors
Texas
$2.57M +$1.31M +1,007 New
PM
16
Precept Management
Texas
$2.55M +$1.3M +1,000 New
Morgan Stanley
17
Morgan Stanley
New York
$2.54M +$225K +173 +21%
VC
18
Voss Capital
Texas
$1.73M +$885K +679 New
Two Sigma Advisers
19
Two Sigma Advisers
New York
$1.71M +$599K +460 +219%
SPC
20
Sigma Planning Corp
Michigan
$1.34M +$26.1K +20 +4%
SMH
21
Sanders Morris Harris
Texas
$1.27M -$136K -104 -17%
Man Group
22
Man Group
United Kingdom
$1.25M -$4.02M -3,088 -86%
DAM
23
DLD Asset Management
New York
$1.14M +$581K +446 New
BFM
24
Boothbay Fund Management
New York
$978K +$362K +278 +265%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$736K -$3.91K -3 -1%
1
2 3

APTO Hedge Fund Activity: Q4 2019 in Review

56 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2019, worth a combined $174M — up 489% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new APTO positions and 9 closed out — a net gain of 25 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.8M. The largest seller was Point72 Asset Management, cutting an estimated $4.14M.

  • 56 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2019, up from 31 in Q3 2019.
  • Funds reported $174M of Aptose Biosciences, Inc. stock for Q4 2019, up 489% quarter-over-quarter.
  • 34 funds opened new Aptose Biosciences, Inc. positions in Q4 2019 and 9 closed out, a net change of +25 holders.
  • The largest Aptose Biosciences, Inc. buyer in Q4 2019 was Consonance Capital Management, an estimated $13.8M added.
  • The largest Aptose Biosciences, Inc. seller in Q4 2019 was Point72 Asset Management, an estimated $4.14M sold.

Based on aggregated 13F filings for Q4 2019.